Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Rani Therapeutics Holdings (Nasdaq: RANI) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rani Therapeutics Holdings (Nasdaq: RANI) announced its participation in the H.C. Wainwright Global Investment Conference, scheduled for September 12-14, 2022. CEO Talat Imran will deliver a presentation on September 12 at 8:30 AM EST. The conference will be accessible virtually and in-person, with a webcast available via the Investor Relations section of Rani's website. Rani Therapeutics focuses on innovative oral delivery systems for biologics, utilizing its patented RaniPill capsules to replace traditional injection methods.
Details
News Market Reaction – RANI
The recorded move for RANI in the trading session of this news was +3.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company will present at the H.C. Wainwright Global Investment Conference, taking place September 12 - 14, 2022 virtually and in-person.
Talat Imran, Chief Executive Officer of Rani, is scheduled to present on Monday, September 12 at 8:30 AM EST / 5:30 AM PST.
Interested parties can access the on-demand webcast for this conference from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replay will be available after the conclusion of the conference for approximately 90 days.
About Rani Therapeutics
Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Rani has developed RaniPill capsules, which are a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill capsules. For more information, visit ranitherapeutics.com.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
Source: Rani Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.